ERBB2 and breast carcinoma: Moreover, a separate study showed that pyrotinib monotherapy was effective in luminal/HER2-low (IHC 2+, ISH negative) and luminal/HER2-positive breast cancers, with enhanced efficacy when combined with chemotherapy, but no benefit was observed in luminal/HER2-low (IHC 1+) [165].